How did Leap Therapeutics' expenses impact profits in Q4 2024?

Leap Therapeutics' expenses had a significant impact on profits in Q4 2024, with the company reporting a net loss of $15.43 million for the quarter. The following highlights the key expenses that contributed to this loss:

1. **Operating Expenses**: The company's operating expenses for Q4 2024 were $13.11 million. This includes costs related to the development and management of the company's drug pipeline, as well as general administrative expenses.
2. **Research and Development Expenses**: Leap Therapeutics incurred R&D expenses of $3.01 million in Q4 2024. These expenses are critical for the company's ongoing clinical trials and the development of new therapeutics.
3. **Selling, General, and Administrative Expenses**: Although not reported separately, the company's selling, general, and administrative expenses are likely to be included in the operating expenses figure. These expenses relate to marketing, sales, and administrative activities necessary for the company's operations.

The total of these expenses, along with any other operational costs, would have significantly impacted the company's profit margins. The absence of revenue, as reported, indicates that the expenses were not offset by any sales or licensing income during the quarter. The high RSI (29.84) suggests that the stock was potentially overbought, which could be a signal for investors to be cautious about the stock's short-term performance.

In conclusion, the combination of operating, R&D, and potentially other expenses, coupled with the lack of revenue, resulted in Leap Therapeutics' substantial net loss in Q4 2024.